TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Moderna and Merck say a Phase 3 trial of personalized mRNA vaccine intismeran with Keytruda reduced the risk of melanoma recurrence or death by 42% compared with Keytruda and placebo. At two years, 82% of the vaccine group and 70% of the comparison group were alive without recurrence. The companies’ announcement does not provide full trial data, including participant numbers and detailed safety results.
Moderna and Merck said a Phase 3 trial found that adding the personalized mRNA cancer vaccine intismeran to Keytruda reduced patients’ risk of melanoma recurrence or death by 42% compared with Keytruda and placebo. At two years, 82% of patients in the vaccine group were alive without recurrence, versus 70% in the comparison group, according to the companies’ announcement.
The trial involved patients with resected melanoma receiving adjuvant treatment—that is, treatment after surgery intended to lower the chance that cancer returns. One group received intismeran, also known as mRNA-4157, with Merck’s immunotherapy Keytruda; the comparison group received Keytruda with a placebo. The reported 42% figure describes a reduction in the relative risk of recurrence or death, not a 42-percentage-point difference in the share of patients who remained recurrence-free.
The companies also reported a benefit on distant metastasis-free survival, a measure of time without cancer returning in a different part of the body or death. They said the vaccine combination reduced the risk of distant metastasis or death by 38% relative to Keytruda and placebo. At the reported assessment, 88.5% of the combination group were alive without distant metastasis, compared with 80% of the comparison group.
The results were described in a company announcement, and the available report does not include the full trial publication or a detailed accounting of adverse events. The two-year figures are interim time-based outcomes, not proof that every patient benefits or that the vaccine prevents recurrence permanently. The companies’ findings concern this particular melanoma setting and treatment combination.
A New Option After Melanoma Surgery
The results could matter to people treated for melanoma whose cancer has been surgically removed but may still return. In this setting, the reported improvement in recurrence-free survival offers a potential way to lower that risk when the vaccine is used alongside an existing immunotherapy. The absolute difference reported at two years—82% versus 70% alive without recurrence—helps show the observed outcome in each group, while the 42% figure expresses relative risk reduction.
The findings also extend investigation of personalized cancer vaccines into a large Phase 3 study. If the results withstand review and lead to regulatory approval, the approach could add a treatment choice for eligible patients. It is not yet a broadly available or established replacement for current care on the basis of this announcement alone. Decisions about post-surgery treatment remain a matter for patients and their oncology teams.
Products Worth Considering
Bowflex PR1000 Home Gym
Garmin Forerunner 165 GPS Running Smartwatch, 43 mm, Black
Withings BPM Vision Blood Pressure Monitor with Wi-Fi and Bluetooth
As an affiliate, we earn on qualifying purchases.
How the Personalized Vaccine Works
Intismeran is designed using genetic information from an individual patient’s tumor. Researchers compare sequences from cancer cells and healthy cells to identify mutations found in the tumor. The synthetic mRNA vaccine can encode up to 34 selected mutations, with the aim of directing an immune response toward cancer-specific targets. It is personalized rather than a single identical vaccine for all patients.
Keytruda, the comparator treatment in both trial groups, is an established immunotherapy. A previous Phase 2 study of the vaccine combination reported a 49% reduction in recurrence-or-death risk and a 59% reduction in distant-metastasis-or-death risk over five years, according to the source report. The newer Phase 3 figures are smaller, but they come from a later-stage trial and are reported at a two-year assessment. The different follow-up periods mean the percentages should not be treated as direct, like-for-like measures.
“The trial “is the first Phase 3 study to demonstrate a clinically meaningful improvement in RFS and DMFS over standard-of-care KEYTRUDA in patients with resected melanoma.””
— Dean Li, president of Merck Research Laboratories
Full Trial Data Still Pending
The company announcement does not provide enough detail to independently assess the results. The available source does not state the number of participants, the full statistical analysis, confidence intervals, or a complete breakdown of side effects and treatment discontinuations. Those details are needed to evaluate the reliability and clinical meaning of the reported differences.
It is also unclear from the supplied information how long follow-up will continue, whether benefits differ among patient groups, and what regulatory steps or timing the companies expect. The reported endpoints include death as well as recurrence or distant metastasis, but the announcement does not give separate death rates. The 42% figure should be understood as a relative reduction in the combined risk measure, alongside the reported two-year group outcomes.
Publication and Regulatory Steps
The next points to watch are release of the complete Phase 3 results and any peer-reviewed publication or presentation that supplies trial methods, participant characteristics, statistical measures and safety findings. Such information would allow clinicians and researchers to assess the benefit-risk profile beyond the headline percentages.
Moderna and Merck may also provide information about their regulatory plans, but the supplied report does not confirm an application or review schedule. Until more data and any required regulatory decisions are available, intismeran should be understood as an investigational treatment in this account, not as a newly approved standard of care.
Key Questions
What does the 42% reduction mean?
It is a reported relative reduction in the risk of recurrence or death for patients receiving intismeran with Keytruda compared with patients receiving Keytruda and placebo. It does not mean 42% more patients avoided recurrence. At two years, the reported recurrence-free proportions were 82% and 70%, respectively.
What is intismeran?
Intismeran, also called mRNA-4157, is a personalized mRNA vaccine designed around selected mutations in a patient’s tumor. The trial tested it alongside Keytruda in patients with melanoma removed by surgery.
Did the vaccine reduce distant spread as well?
Moderna and Merck reported a 38% reduction in the risk of distant metastasis or death compared with Keytruda and placebo. They said 88.5% of the combination group and 80% of the comparison group were alive without distant metastasis at the reported assessment.
Is the vaccine approved for melanoma treatment?
The source material describes trial findings and does not report an approval. Regulatory status and next steps are not specified in the available announcement.
What information is still needed?
Readers need the full trial report, including participant numbers, statistical details, follow-up and comprehensive safety results. That information would help clarify how durable the benefit is and which patients may be most likely to benefit.
Source: hn
